Overview

Safety and Efficacy Study of a Testosterone Eye Drop for the Treatment of Meibomian Gland Dysfunction

Status:
Completed
Trial end date:
2009-04-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to assess the safety and efficacy of testosterone 0.03% ophthalmic solution compared to vehicle for the treatment of meibomian gland dysfunction.
Phase:
Phase 2
Details
Lead Sponsor:
H. Jerome Crampton
ORA, Inc.
Treatments:
Methyltestosterone
Ophthalmic Solutions
Pharmaceutical Solutions
Testosterone
Testosterone 17 beta-cypionate
Testosterone enanthate
Testosterone undecanoate